Mixed Views on US Biosimilar Market
Please take some time to review this article: Mixed views on US biosimilar market
Much was expected of biosimilars and their potential to cut the price of originator with savings projected to reach hundreds of billions. Such expectation at least in the US have proven unrealistic. A report last year (2019) outlined that the US healthcare system barely make savings worth 7 billion dollars annually. AS 2020 makes its halfway, researchers begin to investigate biosimilars in the US to determine how successful their introduction onto the market could be.
Review the following reference and probe the questions below:
How many TFDA approved biosimilars are there on the Taiwan market? What is the reimbursement policy for biosimilars in Taiwan as dictated by the National Insurance of Health?
Pharmacotherapy: Understanding Biotechnology Products
Pharmacotherapy: Understanding Biotechnology Products
Reach your personal and professional goals
Unlock access to hundreds of expert online courses and degrees from top universities and educators to gain accredited qualifications and professional CV-building certificates.
Join over 18 million learners to launch, switch or build upon your career, all at your own pace, across a wide range of topic areas.
